Nel ASA — Director's Dealing 2010

Feb 9, 2010

NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

Reference is made to the notice to the stock exchange on 25 January 2010

regarding commencement of subscription period for the "Subsequent

offering". The subscription period ended on 8 February 2010 and

mandatory notification of trade among primary insiders of DiaGenic ASA

took place. The transactions are described in detail below.

Håkon Sæterøy, Executive Chairman of the Board of DiaGenic ASA, has

through his companies Investor Corporate AS and Investor Partners AS

received 74,802 subscription rights and subscribed for 74,802 shares at

NOK 2.75 per share. Sæterøy`s overall exposure in the Company will

increase to a total of 1,471,279 shares after allotment of the shares in

the issue, in addition to 155,000 warrants (as resolved by the general

meeting on 18 December 2009), and in addition to the TRS agreement with

exposure for 135,000 shares.

Gustav Ingemar Kihlström, Deputy Chairman of the Board of DiaGenic ASA,

received 8,956 subscription rights and has subscribed for 8,956 shares

in this offering at NOK 2.75 per share. Kihlström`s overall exposure in

the Company has increased to a total of 113,956 shares post allotment of

the shares in the offering.

CEO Erik Christensen has entered into a Total Return equity Swap

agreement (TRS) with exposure of 60,000 underlying shares. Expiry date

is 7 May 2010, and the TRS price is NOK 3.39 per share. Christensen

received 12,795 subscription rights and subscribed for 13,000 shares at

NOK 2.75 per share. After allotment of subscribed shares Christensen

will increase his exposure by minimum 12,795 shares. Prior to allotment

of subscribed shares Christensen directly owns a total of 90,000 shares

in addition to the TRS agreement with exposure for 60,000 shares.

Praveen Sharma, Director and board member in DiaGenic ASA, received

195,764 subscription rights and has subscribed for 195,764 shares in

this offering at NOK 2.75 per share. Sharma's overall exposure in the

Company has increased to a total of 2,490,764 shares post allotment of

the shares in the offering in addition to the TRS agreement with

exposure for 700,000 shares.

Anders Lönneborg, Director in DiaGenic ASA, received 247,370

subscription rights and has sold 240,000 subscription rights at NOK 0.55

per subscription right, and subscribed for 7,370 shares in this offering

at NOK 2.75 per share. Lönneborg's overall exposure in the Company has

increased to a total of 2,907,370 shares post allotment of the shares in

the offering.

Morten Sten Johansen, Director in DiaGenic ASA, received 11,942

subscription rights and has subscribed for 20,000 shares in this

offering at NOK 2.75 per share. Johansen's overall exposure in the

Company will increase by minimum 11,942 shares. Prior to the allotment

of shares in this offering Johansen owns a total of 140,000 shares in

the Company.

Dag Christian Christiansen, Director in DiaGenic ASA, received 21,325

subscription rights and has sold 11,325 subscription rights at NOK 0.70

per subscription right, and subscribed for 10,000 shares in this

offering at NOK 2.75 per share. Christiansen's overall exposure in the

Company has increased to a total of 260,000 shares post allotment of the

shares in the offering.

Maria Holmlund, board member in DiaGenic ASA, received 853 subscription

rights and has subscribed for 1,000 shares in this offering at NOK 2.75

per share. Holmlund's overall exposure in the Company will increase by

minimum 853 shares. Prior to the allotment of shares in this offering

Holmlund owns a total of 10,000 shares in the Company.

Ingrid Alfheim, board member in DiaGenic ASA, received 558 subscription

rights and has subscribed for 7,000 shares in this offering at NOK 2.75

per share. Alfheim's overall exposure in the Company will increase by

minimum 558 shares. Prior to the allotment of shares in this offering

Holmlund owns a total of 6,545 shares in the Company.

Torbjørn Lindahl, head of bioinformatics and IT in DiaGenic ASA,

received 2,986 subscription rights and has subscribed for 3,000 shares

in this offering at NOK 2.75 per share. Lindahl's overall exposure in

the Company will increase by minimum 2,986 shares. Prior to the

allotment of shares in this offering Lindahl owns a total of 35,000

shares in the Company.

Ruben Ekbråten, Financial Controller in DiaGenic ASA, received 853

subscription rights and has subscribed for 8,000 shares in this offering

at NOK 2.75 per share. Ekbråten's overall exposure in the Company will

increase by minimum 853 shares. Prior to the allotment of shares in this

offering Ekbråten owns a total of 10,000 shares in the Company.

Contact:

MD PhD Erik Christensen, CEO

Telephone: +47 95939918

e-mail: erik.christensen@diagenic.com